Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASH 2022 | The role of alloSCT for R/R LBCL in the era of CAR-T therapy

Alberto Mussetti • 12 Dec 2022

ASH 2022

Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T

Alberto Mussetti, MD, Catalan Institute of Oncology, Barcelona, Spain, discusses the role of allogeneic stem cell transplantation (alloSCT) in patients with large B-cell lymphoma (LBCL), highlighting its value in patients who relapse or progress after CAR-T therapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

BMS: Consultancy; Takeda: Honoraria; Gilead: Research Funding; Jazz Pharmaceuticals: Consultancy.

Comparing the outcomes of patients with LBCL receiving alloSCT versus anti-CD19 CAR-T therapy

Alberto Mussetti • 12 Dec 2022

Using artificial intelligence to estimate overall mortality and non-relapse mortality after alloSCT

Alberto Mussetti • 12 Dec 2022

The importance of assessing response to CD19 CAR-T therapy in LBCL to confirm disease persistence

Alberto Mussetti • 28 Oct 2022

The role of CAR-T therapy in high-risk LBCL in the first and second-line settings

Alberto Mussetti • 28 Oct 2022

Related Videos

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024

The role of CAR-T therapy for lymphoma in 2024: expert session highlights

Sridhar Chaganti • 16 Apr 2024

Promising novel immunotherapeutic approaches in lymphoma

Gloria Iacoboni • 15 Apr 2024

AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study

Jacopo Mariotti • 15 Apr 2024